SCHEDULE: TCG Crossover Discloses 7.8% Stake in LB Pharmaceuticals

TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, and Chen Yu have reported a passive beneficial ownership of 7.8% in LB Pharmaceuticals Inc.

Summary

• TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, and Chen Yu (collectively, the "Reporting Persons") have filed a Schedule 13G.
• The Reporting Persons collectively beneficially own 1,745,015 shares of LB Pharmaceuticals Inc. Common Stock.
• This ownership represents 7.8% of the total outstanding Common Stock of LB Pharmaceuticals Inc.
• The percentage is based on 22,442,989 shares of Common Stock outstanding as of September 12, 2025, as reported by the Issuer.
• The Reporting Persons have shared voting and dispositive power over all 1,745,015 shares.
• The investment is passive, and the Reporting Persons certify that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 7

Explanation: The filing indicates a significant passive investment by TCG Crossover in LB Pharmaceuticals, which can be interpreted as a vote of confidence from a sophisticated investor. However, it is a standard disclosure of ownership and does not contain operational or financial performance updates.

Positives

• A prominent institutional investment group, TCG Crossover, has taken a significant 7.8% passive stake in LB Pharmaceuticals Inc.
• This indicates a vote of confidence from a sophisticated investor in the company's long-term prospects and valuation.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding LB Pharmaceuticals Inc.'s future performance or strategic direction.

Management Comments

• The Reporting Persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

The investment by TCG Crossover, a crossover fund, in LB Pharmaceuticals Inc. suggests an interest in companies potentially in growth stages or transitioning within the pharmaceutical or biotechnology sector. Such investments are common as funds seek opportunities in innovative or developing companies.

Stakeholder Impact

• Shareholders: Increased institutional ownership may lend credibility and potentially stability to the stock, signaling external validation of the company's prospects.
• Management: Awareness of a significant passive investor on the cap table, though without intent to influence control.

Key Dates

Recommendation

The filing indicates a significant passive stake by TCG Crossover, a notable institutional investor, in LB Pharmaceuticals. While this suggests a vote of confidence, the Schedule 13G itself does not provide operational or financial performance data to warrant a stronger recommendation. Investors should consider this ownership alongside the company's fundamentals and broader market conditions.

Keywords

LB Pharmaceuticals, TCG Crossover, Schedule 13G, beneficial ownership, common stock, institutional investment, passive stake, pharmaceuticals